CureVac CVAC -3.47% NV said Wednesday its experimental Covid-19 vaccine was 47% effective against the disease in an interim analysis of a large clinical trial, a disappointing outcome likely to dim the shot’s prospects for wider use.
The setback could hinder vaccination campaigns in Europe because the German company has a contract with the European Commission to supply up to 405 million doses. CureVac has struck partnerships with big pharmaceutical companies GlaxoSmithKline GSK 0.22% PLC and Novartis AG NVS -0.13% to help make doses.
CureVac’s vaccine uses a gene-based technology, messenger RNA, similar to the technology used by Moderna Inc. and Pfizer Inc., with its partner BioNTech SE, to make Covid-19 vaccines.
In comparison, those vaccines were at least 94% effective in large clinical trials last year before new virus variants spread significantly. The Moderna and Pfizer shots have formed the backbone of mass vaccination campaigns in the U.S. and other countries.
CureVac’s vaccine is slightly different than the Pfizer and Moderna shots, with a formulation that allows it to be stored at higher temperatures than the other shots.
STAY INFORMED
Get a coronavirus briefing six days a week, and a weekly Health newsletter once the crisis abates: Sign up here.
CureVac conducted, with partner Bayer AG, a combined Phase 2/3 clinical trial of its vaccine, enrolling about 40,000 people in 10 countries in Latin America and Europe, starting in December.
Study volunteers received two doses of either the CureVac vaccine or a placebo, and researchers kept track of how many in either group came down with Covid-19.
The spread of new coronavirus variants may have played a role in the disappointing efficacy, CureVac said.
Some 57% of Covid-19 cases for which virus sequence data were available were caused by variants of concern—those that can be transmitted more easily or may cause more severe disease—and most of the remaining cases were caused by other, less characterized variants, the company said.
“While we were hoping for a stronger interim outcome, we recognize that demonstrating high efficacy in this unprecedented broad diversity of variants is challenging,” said CureVac Chief Executive Dr. Franz-Werner Haas.
The company said the vaccine’s efficacy in the trial varied by age, with results suggesting effectiveness in younger people but not conclusive efficacy in those above age 60.
CureVac’s early work on a Covid-19 vaccine last year initially caught the attention of then President Donald Trump. In March 2020, Germany’s government accused the U.S. of trying to lure CureVac to relocate to the U.S. to work on a vaccine.
The company continued to develop the shot after its founder, who had returned as CEO, suffered a crippling stroke and took a medical leave.
Write to Peter Loftus at [email protected]
Copyright ©2020 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
